By Fineline Cube Bio-Thera Solutions Ltd. (SHA: 688177) announced it has received marketing approval from Singapore’s Health Sciences Authority for BAT2206, a biosimilar to Johnson & Johnson’s blockbuster autoimmune therapy Stelara (ustekinumab), significantly broadening treatment access across multiple inflammatory conditions in both adult and pediatric populations.
Regulatory Milestone
| Item | Detail |
|---|---|
| Company | Bio-Thera Solutions Ltd. (SHA: 688177) |
| Product | BAT2206 (ustekinumab biosimilar) |
| Reference Product | Stelara (J&J/Janssen) |
| Regulatory Authority | Singapore Health Sciences Authority |
| Approval Date | 11 Jun 2026 |
| Indications Approved | Adult: Moderate-to-severe plaque psoriasis (PsO), active psoriatic arthritis (PsA), moderate-to-severe active Crohn’s disease (CD) Pediatric: Moderate-to-severe plaque psoriasis (PsO), moderate-to-severe active Crohn’s disease (CD) |
Drug Profile & Mechanism of Action
- Molecule: Fully human monoclonal antibody (biosimilar to ustekinumab)
- Target: p40 subunit shared by interleukin-12 (IL-12) and interleukin-23 (IL-23)
- Mechanism: High-affinity binding to p40 subunit blocks interaction with cell surface receptors, disrupting IL-12- and IL-23-mediated signaling pathways critical in inflammatory and immune responses
- Therapeutic Class: Immunomodulator targeting key cytokines in autoimmune disease pathogenesis
BAT2206 represents Bio-Thera’s strategic entry into the high-value biologics market for chronic inflammatory diseases. By targeting the shared p40 subunit of IL-12 and IL-23—cytokines that drive inflammation in multiple autoimmune conditions—the biosimilar offers a comprehensive therapeutic approach across diverse patient populations.
Market Impact & Commercial Strategy
- Singapore Market Opportunity: Estimated 15,000-20,000 patients across approved indications with limited biosimilar competition in the IL-12/23 inhibitor class
- Pricing Advantage: Expected to be priced 25-35% below originator Stelara, aligning with typical biosimilar discount ranges in developed Asian markets
- Global Expansion: Singapore approval serves as a regulatory gateway for broader ASEAN market access, with submissions planned in Malaysia, Thailand, and Indonesia by Q4 2026
- Competitive Landscape: First ustekinumab biosimilar approved in Singapore; competes against J&J’s originator and emerging biosimilars from Celltrion and Samsung Bioepis in other markets
- Revenue Projection: Bio-Thera forecasts SGD 45-60 million (USD 33-44 million) in annual peak sales across Southeast Asia, representing approximately 8-12% of the company’s projected 2028 revenue
The approval positions Bio-Thera as a leading Chinese biopharmaceutical exporter in the global biosimilars space, leveraging Singapore’s reputation as a regulatory benchmark for the broader Asia-Pacific region.
Forward‑Looking Statements
This brief contains forward-looking statements regarding regulatory approvals, market opportunities, and commercial projections. Actual results may differ due to competitive dynamics, pricing pressures, and regulatory developments in target markets.-Fineline Info & Tech